Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar TMFSarahGen (99.81) Submitted: 12/30/2011 3:07:55 PM : Outperform Start Price: $1.53 AEZS Score: -64.96

Fool biotech board likes this.

Report this Post Reply

Featured Broker Partners


Advertisement